CAP 3 Biochemical | CAP3 biochemical

CAP 3

Cat. Num. AAA227352

• Purity: 98%
• Synonyms: CAP 3; N/A; ISIS-420915 sodium; CAP3 biochemical

• Purity/Purification: 98%

• Solubility: DMF: 5 mg/mL; ; PBS (pH 7.2): 3mg/mL; ; DMSO: 10 mg/mL; ; Ethanol: 10 mg/mL; <1mg/ml refers to the product slightly soluble or insoluble
• Preparation and Storage: Powder: -20 degree C for 3 years; In solvent: -80 degree C for 2 years

Structure

(Inotersen sodium, CAS 1432726-13-0)

Structure

(Inotersen sodium, CAS 1432726-13-0)

Related Product Information for CAP3 biochemical

CAP 3 is a cholic acid-peptide conjugate (CAP) with antibacterial activity. It is active against the Gram-negative bacteria E. coli, K. pneumoniae, and A. baumanii (MIC99s = 8, 16, and 16 uM, respectively). CAP 3 increases the fluidity of model Gram-negative bacterial membranes and binds to LPS in vitro. It reduces the biomass and number of colony-forming units in E. coli biofilms in a concentration-dependent manner. CAP 3 inhibits E. coli biofilm formation on catheters implanted in mice infected with E. coli at the incision site when applied as a coating on the catheters. CAP 3 (40 mg/kg) also reduces bacterial load in E. coli-infected wounds in mice. It is cytotoxic to A459 cells (IC50 = 56.4 uM) and has hemolytic activity against human red blood cells with a 50% lysis (HC50) value of 48 uM.

References

1. Ackermann EJ, et, al. Suppressing transthyretin production in mice, monkeys and humans using 2nd-Generation antisense oligonucleotides. Amyloid. 2016 Sep;23(3):148-157.
2. Mathew V, et, al. Inotersen: new promise for the treatment of hereditary transthyretin amyloidosis. Drug Des Devel Ther. 2019 May 6;13:1515-1525.
3. Benson MD, et, al. Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018 Jul 5;379(1):22-31.